The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.

TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...

TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

Cells use homologous recombination to stitch double-stranded breaks (DSB) back together and the enzyme telomerase to cap exposed ends of a DNA strand with a repetitive DNA sequence called a telomere.

Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of rare diseases and aging-associated diseases using its ZSCAN4 technology and mRNA platform ...

View Full Profile. Learn about our Editorial Policies. On its website last week (April 22), BioViva reported the first results of Parrish’s treatment: the telomeres of her leukocytes grew longer, from ...

“This is the first mouse model with truly humanized telomeres because telomerase isn’t expressed in adult tissues in this model,” said Jiyue Zhu, PhD, professor, college of pharmacy and phar ...